Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
MBG453 - TIM-3 antagonist
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04150029 STIMULUS-AML1 (CMBG453C12201)
Unfit acute myeloid leukaemia
Phase 2
86
Incidence of dose limiting toxicities (Safety run-in patients only)
Percentage of subjects achieving complete remission (CR)
Single arm safety and efficacy study of sabatolimab in combination with azacitidine
and venetoclax
Target Patients
Newly diagnosed adult AML patients who are not suitable for treatment with
intensive chemotherapy
Read-out Milesstone(s)
2023
Publication
TBD
108 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation